Comparison of characteristics and clinical findings between patients having a poor visual prognosis (BCVA≤20/50) and patients with a preserved visual prognosis (BCVA >20/50)
| Characteristic | Poor visual prognosis (BCVA ≤20/50) n=9 | Preserved visual prognosis (BCVA >20/50) n=74 | p Value |
|---|---|---|---|
| Age (years)* | 59 (50; 67) | 51 (34; 62) | 0.062 |
| Gender (female) | 9 (100%) | 55 (74.3%) | 0.11 |
| Follow-up period (months)* | 91 (48; 110) | 60 (43; 98) | 0.40 |
| Ethnicity | 0.87 | ||
| Caucasian | 7 (78.8%) | 54 (73%) | |
| Non-Caucasian | 2 (22.2%) | 20 (26.3%) | |
| Maghrebin | 2 (22.2%) | 12 (16.2%) | |
| African | 0 | 6 (8.1%) | |
| Asian | 0 | 2 (2.7%) | |
| Familial history of sarcoidosis | 1 (11.1%) | 4 (5.4%) | 0.45 |
| Ophthalmological findings | |||
| Intraocular manifestations | |||
| Anterior | 0 | 17 (23%) | |
| Anterior intermediate | 1 (11.1%) | 10 (13.5%) | |
| Intermediate | 1 (11.1%) | 3 (4.1%) | |
| Posterior | 0 | 11 (14.9%) | |
| Panuveitis | 7 (77.8%) | 33 (44.6%) | |
| Chronic form | 7 (77.8%) | 49 (66.2%) | 0.14 |
| Bilateral involvement | 7 (77.8%) | 56 (75.7%) | 0.71 |
| Granulomatous uveitis | 5 (55.6%) | 40 (57.1%) | 1.00 |
| Elevated IOP | 0 | 10 (13.9%) | 1.00 |
| CME | 8 (88.9%) | 28 (39.4%) | 0.59 |
| PMC | 2 (22.2%) | 22 (31%) | 0.009 |
| Other eye involvement | |||
| Conjunctival node | 1 (11.1%) | 6 (8.2%) | 0.72 |
| Episcleritis | 0 | 1 (1.4%) | 0.71 |
| Scleritis | 0 | 2 (2.7%) | 1.00 |
| Treatment | |||
| Local treatment | |||
| Eye drops | 6 (66.7%) | 51 (70.8%) | 0.002 |
| Injections | 6 (66.7%) | 11 (15.5%) | 0.11 |
| Systemic therapy | 9 (100%) | 54 (73%) | 0.10 |
| Oral steroids | 9 (100%) | 52 (71.2%) | 0.097 |
| Methotrexate | 4 (44.4%) | 14 (18.9%) | 0.54 |
| Other immunosuppressant | 0 | 14 (18.9%) | 0.030 |
| Oral corticoid dependence | 4 (44.4%) | 9 (12.2%) | 0.061 |
| Systemic therapy duration (months)* | 36 (24; 74) | 18 (0; 36) | 0.0004 |
| Systemic therapy at last report | 9 (100%) | 28 (37.8%) | 0.0005 |
| Persistent ocular inflammation | 5 (55.6%) | 4 (5.4%) | |
| Indication for systemic therapy | 0.41 | ||
| Ocular | 8 (88.9%) | 37 (68.5%) | |
| Extraocular | 0 | 6 (11.1%) | |
| Both | 1 (11.1%) | 11 (20.4%) | |
Data are expressed as number and percentage, n (%); or * median (1st; 3rd quartile).
BCVA, best-corrected visual acuity; CME, chronic macular oedema; elevated IOP, chronically elevated intraocular pressure >21 mm Hg resulting from damage of angle; PMC, peripheral multifocal choroiditis.